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Abstract—Acoustic Cluster Therapy (ACT) employs an 
intravenously-injected dispersion of clusters of microbubbles and 
oil microdroplets, in combination with ultrasound directed at the 
tumor, to enhance the delivery of a co-administered drug. 
Diagnostic ultrasound activates the clusters, causing the droplets 
to change phase and become large (> 20 m) bubbles which lodge 
in the tumor capillaries. Delivery-enhancement is then achieved 
using a low-frequency (e.g. 300 kHz) ultrasound field also 
directed at the tumor, which causes the stationary bubbles to 
pulsate whilst in direct contact with the vascular endothelium. 
ACT has been shown to significantly increase the efficacy of 
various chemotherapeutics in a variety of tumor models in mice. 
Here we demonstrate through preclinical in-vivo experiments 
that the efficacy of treating human triple negative breast cancer 
in mice with liposomal doxorubicin (Doxil®) is significantly 
enhanced by ACT; for example, 63 % of animals achieved 
complete, stable remission, in the group treated with the drug 
and ACT versus only 10 % for Doxil® alone (p < 0.02). We also 
show in the same experiments that the ACT contrast 
enhancement obtained under ultrasound activation of the ACT 
clusters, either before or during treatment, holds promise as an 
imaging biomarker for predicting response.  
Keywords—ACT, cancer treatment response, drug delivery, 
imaging biomarker, microbubble 
I. INTRODUCTION 
Acoustic Cluster Therapy (ACT) is designed to overcome 
some of the limitations of conventional microbubbles for 
enhancing drug delivery in combination with ultrasound [1, 2]. 
It involves co-administration of a dispersion of clusters 
containing a microbubble and an oil microdroplet [3], together 
with an unmodified medicinal drug such as a chemotherapeutic 
agent.  Diagnostic ultrasound directed at the tumor to be treated 
vaporizes the droplets, turning the clusters into bubbles of 
diameter > 20 µm. These large bubbles lodge in, and possibly 
occlude, tumor capillaries for many minutes, during which 
time low-frequency ultrasound (e.g. 300 kHz) is applied to 
make them pulsate, enhancing the delivery of any co-
administered drug via a range of biomechanical effects. This 
has been shown to significantly increase therapeutic efficacy of 
a number of anticancer drugs in various tumor models in mice 
[4-7]. 
In this study we (a) investigated the efficacy of liposomal 
doxorubicin (Doxil
®
) with and without ACT for treatment of 
human, triple negative, breast cancer in mice, and (b) evaluated 
whether the ACT-activation signature reported in a companion 
paper [2] has value for predicting individual therapeutic 
outcome. 
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Figure 1. Therapy rank minus image rank plotted against image rank for all tumours in the ACT+DOX 
group. Perfect prediction of the level of therapeutic response by the image rank would always yield zero for 
the therapy rank minus image rank value. The probability that there was no correlation between image rank 
and therapy rank was 0.0005, assessed using a nonparametric Pearson’s correlation, r = 0.96. 
II. MATERIALS AND METHODS 
A. Animal groups 
Clinical grade liposomal doxorubicin, Doxil
®
 (6 mg/kg, 
maximum tolerated dose) referred to here as DOX, was given 
intravenously to athymic mice when tumors (MDA-MB-231-
luc orthotopic human triple negative breast cancer xenografts) 
had reached a volume of about 209 mm
3
, and again 21 days 
later, either alone or immediately followed by three sequential 
intravenous injections of the ACT cluster-dispersion known as 
PS101. PS101 consisted of a commercially available 
microbubble (Sonazoid™, GE Healthcare) and a microdroplet 
of perfluoromethylcylopentane (PFMCP, F2 Chemicals Ltd, 
UK). Animals were randomized into the following three 
groups, depending on when tumors reached the starting volume 
(7 to 10 per group).  
 Group 1 (PS101+US): 9 animals, no drug, 3 doses of 
PS101 of 2 mL/kg at the first treatment and 3 doses of 
PS101 of 2 mL/kg 21 days later, exposed to 
ultrasound.  
 Group 2 (DOX): 10 animals, Doxil® 8 mg/kg at first 
treatment and 6 mg/kg at second treatment, no PS101, 
not exposed to ultrasound.  
 Group 3 (ACT+DOX): 7 animals, Doxil® 6 mg/kg at 
first treatment and 6 mg/kg at second treatment, 3 
doses of PS101 2 mL/kg at the first treatment and 3 
doses of PS101 2 mL/kg 21 days later, exposed to 
ultrasound. 
B. Treatment 
The apparatus for handling the mice, ultrasound imaging 
and delivery-enhancement insonation is described in a 
companion paper in these proceedings [2]. In this study, 
however, mice were placed in a dorsal recumbent position. For 
each PS101 injection, microdroplet vaporization was achieved 
by 45-s B-mode scanning of the tumor at 8 MHz and a 
mechanical index (MI) of 0.33 [8], using a Toshiba Aplio XG 
scanner and 1204BT transducer. Low-frequency insonation 
then occurred for 5 min at 300 kHz and an MI of 0.15 using a 
custom made, single element bowl transducer (Imasonic) 
focused towards the tumor.  
C. Data analysis 
The ultrasound fundamental echo B-mode tumor ACT-
activation contrast enhancement [2] was determined from the 
ultrasound images recorded during activation and was given a 
visual ranking. This was repeated for all three PS101 injections 
on the first treatment, and all three injections 21 days later. The 
average score (higher value indicates increased contrast and 
activation) was compared with therapeutic response in a 
blinded manner. To score therapeutic response, non-responding 
animals (sacrificed prior to 175 days) were ranked by survival 
time (shorter survival = lower rank) and responders were 
ranked by the day that the tumor volume reached (and stayed 
at) zero (shorter time to reach zero = higher rank).  
III. RESULTS AND DISCUSSION 
ACT substantially improved the therapeutic efficacy of 
Doxil
®
, resulting in 63 % of animals in complete, stable 
remission, versus 10 % for Doxil
®
 alone (p < 0.02). As 
expected, no therapeutic response was observed in the 
PS101+US group, where median survival was 21 days. This 
improved significantly to 67 days for the DOX group (p = 0.04 
for comparison with the PS101+US group), and again 
improved with many animals still surviving at the end of the 
study in the ACT+DOX group (p = 0.0004 for comparison 
with the PS101+US group). In the ACT+DOX group, a 
heterogeneous population of responses was observed, 
facilitating assessment of the ACT-activation contrast score 
against tumor response. 
The B-mode ACT-activation contrast score positively and 
strongly correlated with response rank (r = 0.96, p = 0.0005) 
(Fig. 1), indicating that ACT has theranostic potential such that 
its use during or before treatment may be employed as a 
predictor of therapeutic response, potentially for patient 
management during future clinical use.  
IV. CONCLUSION 
The use of ACT with Doxil
®
 substantially improves 
therapeutic response of human triple negative breast cancer in 
mice over treatment with Doxil
®
 alone. This was observed by 
measurements of both tumor size and overall survival. 
The ACT-activation contrast score appears to represent a 
useful biomarker for the prediction of therapeutic response 
which may have value for patient stratification and 
management. Future work to numerically quantify and 
automate the measurement of such indices would assist clinical 
translation of this potentially promising approach to improving 
treatment outcome. 
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